EGFR Resisters/LUNGevity issues RFA for FY21 award program in EGFR-positive lung cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

EGFR Resisters and LUNGevity Foundation have issued a Request for Application for the EGFR-Positive lung cancer research program.

Funded research is expected to include at least one aim that is translational and must be directly related to improvement in patient outcomes and/or lead to a clinical trial. The EGFR-Positive award is open to researchers at U.S. and international institutions. At the time of application, an international candidate must name a co-principal investigator who is employed at a U.S. institution. A successful applicant may receive up to $200,000 over an award term of two years.

The Request for Applications will be posted as of June 18 on the LUNGevity website and on the proposalCENTRAL website. For more information, contact Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.

Table of Contents

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login